Phase II study with pharmacodynamic evaluation of docetaxel-prednisone (DP) in combination with metronomic cyclophosphamide (CTX) and celecoxib (C) as first line treatment in castration resistant prostate cancer (CRPC)

被引：0
|
作者：
Fontana, A. [1 ]
Galli, L. [2 ]
Derosa, L. [2 ]
Minuti, G. [2 ]
D'Arcangelo, M. [2 ]
Bursi, S. [2 ]
Landi, L. [2 ]
Bocci, G. [3 ]
Santini, D. [4 ]
Falcone, A. [3 ]
机构：
[1] Azienda Osped Univ Pisana, Pisa, Italy
[2] ASL6 Livorno, Med Oncol, Livorno, Italy
[3] Univ Pisa, Pisa, Italy
[4] Univ Campus Biomed, Rome, Italy
来源：
EJC SUPPLEMENTS | 2009年 / 7卷 / 02期
关键词：
D O I：
10.1016/S1359-6349(09)71414-4
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：417 / 417
页数：1
相关论文
共 50 条
  • [41] Phase I study of azacitidine, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer (CRPC) previously treated with docetaxel-based therapy.
    Singal, R.
    Ramachandran, K.
    Gordian, E.
    Reis, I. M.
    Zhao, W.
    Quintero, C. A.
    Mayo, C.
    Auguste, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [42] Randomised phase II/III study of docetaxel with or without risedronate in patients with metastatic Castration Resistant Prostate Cancer (CRPC), the Netherlands Prostate Study (NePro)
    Meulenbeld, H. J.
    van Werkhoven, E. D.
    Coenen, J. L. L. M.
    Creemers, G. J.
    Loosveld, O. J. L.
    de Jong, P. C.
    ten Tije, A. J.
    Fossa, S. D.
    Polee, M.
    Gerritsen, W.
    Dalesio, O.
    de Wit, R.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 (16) : 2993 - 3000
  • [43] Phase II study of docetaxel re-treatment in docetaxel-pretreated castration-resistant prostate cancer
    Di Lorenzo, Giuseppe
    Buonerba, Carlo
    Faiella, Adriana
    Rescigno, Pasquale
    Rizzo, Mimma
    Autorino, Riccardo
    Perdona, Sisto
    Riccardi, Nando
    Scagliorini, Sarah
    Scognamiglio, Florinda
    Masala, Daniele
    Ferro, Matteo
    Palmieri, Giovannella
    Aieta, Michele
    Marinelli, Alfredo
    Altieri, Vincenzo
    De Placido, Sabino
    Carteni, Giacomo
    BJU INTERNATIONAL, 2011, 107 (02) : 234 - 239
  • [44] A multicenter phase II study of abiraterone acetate (AA) in docetaxel pretreated castration-resistant prostate cancer (CRPC) patients (pts)
    Reid, A. H.
    Attard, G.
    Danila, D.
    Ryan, C. J.
    Thompson, E.
    Kheoh, T.
    Molina, A.
    Small, E.
    Scher, H.
    De-Bono, J. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [45] Niclosamide in combination with abiraterone and prednisone in men with castration-resistant prostate cancer (CRPC): initial results from a phase Ib/II trial.
    Pan, Chong-Xian
    Lara, Primo
    Evans, Christopher P.
    Parikh, Mamta
    Dall'era, Marc
    Liu, Chengfei
    Robles, Daniel
    Gao, Allen
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [46] Phase II trial of combination therapy with intravenous bevacizumab (B), oral satraplatin (S), and prednisone (P) in docetaxel-pretreated (DP) metastatic castrate-resistant prostate cancer (CRPC)
    Vaishampayan, U. N.
    Heilbrun, L. K.
    Dickow, B.
    Heath, E. I.
    Smith, D. W.
    Baranowski, K.
    Cher, M. L.
    Powell, I.
    Pontes, J. E.
    Fontana, J. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [47] Phase II study of first-line sagopilone plus prednisone in patients with castration-resistant prostate cancer: a phase II study of the Department of Defense Prostate Cancer Clinical Trials Consortium
    T M Beer
    D C Smith
    A Hussain
    M Alonso
    J Wang
    M Giurescu
    K Roth
    Y Wang
    British Journal of Cancer, 2012, 107 : 808 - 813
  • [48] Phase II study of first-line sagopilone plus prednisone in patients with castration-resistant prostate cancer: a phase II study of the Department of Defense Prostate Cancer Clinical Trials Consortium
    Beer, T. M.
    Smith, D. C.
    Hussain, A.
    Alonso, M.
    Wang, J.
    Giurescu, M.
    Roth, K.
    Wang, Y.
    BRITISH JOURNAL OF CANCER, 2012, 107 (05) : 808 - 813
  • [49] A phase II study of onvansertib in combination with abiraterone and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC).
    Einstein, David Johnson
    Choudhury, Atish Dipankar
    Saylor, Philip James
    Patterson, Jesse Christopher
    Croucher, Peter
    Ridinger, Maya
    Erlander, Mark G.
    Yaffe, Michael B.
    Bubley, Glenn
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [50] A phase II study of onvansertib in combination with abiraterone and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Einstein, David Johnson
    Choudhury, Atish Dipankar
    Saylor, Philip James
    Werner, Lillian
    Erlander, Mark G.
    Ridinger, Maya
    Bubley, Glenn
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
12345